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Highlights 
• Using the German HTA guidelines, the ICER is not taken into consideration. Instead, the
efficiency frontier  was introduced as an alternative, to avoid the use of QALYs and the
setting of willingness-to-pay thresholds.
• We conducted the first direct comparison of the German efficiency frontier methodology
to the conventional ICER, using sacubitril/valsartan,  a new treatment for patients with
chronic heart failure with a reduced ejection fraction.
• Sacubitril/valsartan has a favourable ICER in the German setting, comparable to other
European countries. However, using the efficiency frontier, the results would inform




Objectives: To assess the cost-effectiveness of new treatments in Germany, the efficiency 
frontier (EF) method has been developed. We compared the cost-effectiveness analysis using 
international standards and the German methodology, using the heart failure drug, 
sacubitril/valsartan, as an example. 
Methods: A previously-developed Markov model was adapted to include four treatment options: 
no treatment, enalapril, candesartan and sacubitril/valsartan. The internationally-used 
incremental cost-effectiveness ratio (ICER) was calculated, as well as cost-effectiveness 
acceptability curves (CEAC). Additionally, EFs, net monetary benefits (NMBs) and price-
acceptability curves were created according to German guidelines. All analyses were performed 
from the perspective of the German Statutory Health Insurance. 
Results: The base-case ICER for sacubitril/valsartan compared to enalapril, is €19,300/QALY. 
On the CEAC, sacubitril/valsartan is most likely to be cost-effective, out of all included 
comparators, from a hypothetical willingness-to-pay threshold of €18,250/QALY onwards. No 
EF could be constructed for the base case. Taking the uncertainty of the input parameters in 
account for the probabilistic sensitivity analysis, a NMB of around –€14.000 was calculated, 
depending on the outcome considered, with the NMB being zero at a daily price for 
sacubitril/valsartan ranging from €1.52 to €1.67. 
Conclusions: We calculated an ICER for Germany, comparable to previously published cost-
effectiveness analyses for Europe, which widely concluded sacubitril/valsartan to be cost-
effective. Using the German EF approach, a considerable discount needs to be applied before 




In Germany, pharmaceutical companies do not need to perform a cost-effectiveness analysis for 
new drugs to gain market authorization. Instead prices are negotiated between the statutory 
health insurance funds and the pharmaceutical companies.1,2 An economic evaluation is merely 
one of the tools that can be used to negotiate a reimbursement price, but is seldom used.1,3 If an 
economic evaluation is commissioned in this process, the Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen (IQWIG) is responsible for its assessment; it has 
developed the concept of the efficiency frontier (EF) as a method to compare the cost-
effectiveness of interventions.1,2,4,5 The benefits and pitfalls of this approach, compared to the 
more internationally-common cost-effectiveness/-utility analysis, has been debated 
internationally.6–9  
Internationally, Incremental Cost-Effectiveness Ratios (ICERs) are commonly used as outcomes 
of cost-effectiveness analyses, which is the costs per Quality-Adjusted Life Year (QALY) 
gained. This outcome has the advantage that it enables transferability of cost-effectiveness 
analyses between different diseases.10,11 The methods to create an ICER also have some 
challenges, such as difficulties in assessing disease-specific outcomes with general instruments; 
differences in health-related quality of life assessment between informants such as patients and 
the public; and the choice of a willingness-to-pay threshold to decide on the cost-effectiveness of 
an intervention.6,12 Using the EF as an outcome to decide whether a new intervention is cost-
effective, circumvents these challenges.5,13 As an alternative to QALYs, disease-specific, health-
related outcomes can be used and the threshold, created from the various alternatives for a 
specific disease, can be used to assess the cost-effectiveness.5,13 This however, comes at a major 
disadvantage: different disease areas cannot be compared.8 Additionally, the costs of the existing 
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interventions in a certain disease field have a profound effect on the possible costs of an 
innovative intervention.7 
Chronic Heart Failure (CHF) has a prevalence of around 1.7% and a one-year all-cause mortality 
of 23% among newly diagnosed CHF patients.14 CHF has a large impact on the German 
healthcare budget: the costs per patient are estimated to be €2100-€9100, with 45-72% of the 
costs originating from hospitalizations.15 In 2017, over 460,000 hospitalizations were caused by 
HF (over 2% of total hospitalizations) and the total costs of HF were over €5.2 billion in 2015 
(over 1.5% of total healthcare expenditure).16,17 
In 2015, sacubitril/valsartan (Entresto™, previously known as LCZ696), a new drug for the 
treatment of CHF with a reduced ejection fraction (HF-REF), was approved by the European 
Medicines Agency (EMA).18 In the PARADIGM-HF trial, reduced mortality and hospitalization 
rates in addition to an improved quality of life were found for sacubitril/valsartan as compared to 
enalapril .19 Subsequent to the approval of sacubitril/valsartan by the EMA, pharmacoeconomic 
evaluations have been published for many other European countries.20–24 In a previous study 
from the Dutch perspective, we concluded that sacubitril/valsartan was cost-effective.20 To date, 
one analysis for Germany has been published, reporting an ICER of €23,401 per life-year 
gained.25 However, the article by Gandjour and Ostwald does not include a comparison to the 
EF.25 
We aim to assess the use of the EF for sacubitril/valsartan, an intervention, which replaces the 
broadly available generic drug classes: angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin receptor blockers (ARB). This includes the assessment of the cost-effectiveness of 
sacubitril/valsartan in Germany, using a previously developed model, adapted to incorporate the 
EF, according to German guidelines.4,5,20 Additionally, we perform a cost-utility analysis using 
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globally-used guidelines, including the calculation of an ICER using QALYs, enabling the 
comparison with results from other countries.  We then compare the conclusions decision makers 
could draw based on the German methodology, using the EF, and the international health 





Model design  
A Markov model, previously published for the Netherlands, which primarily incorporated data 
from the PARADIGM-HF trial, was adapted to the German market.19,20 Monthly cycles were 
used for a time horizon of 30 years. The following four health states were incorporated (Figure 
1): 
• Outpatient treated HF-REF; 
• Hospital admissions to a general ward; 
• Hospital admissions including a stay at the ICU; and 
• Death. 
All patients started in the outpatient HF-REF state and were admitted to hospital, using the time-
dependent rates as reported in the PARADIGM-HF trial.19 The duration of stay of the 
PARADIGM-HF trial was used as reported by Packer et al. and 10% of hospital admissions 
included ICU treatment.28,29 In the outpatient setting, the mortality rates were calculated using 
the rates reported in the PARADIGM-HF trial for the death from heart disease and the general 
German population parameters for other causes of mortality.19,30 Mortality and hospitalization 
data from the PARADIGM-HF trial were used, as reported in our analysis for the Netherlands.20  
For the inpatient setting, data published for the CHF population by Corrao et al. were used for 
both mortality and hospitalizations, since the 30-day hospital deaths from PARADIGM-HF were 
not publicly available.31 Rehospitalization rates as published by Desai et al. were used.32 All 
transition probabilities are displayed in supplementary table 1 and all treatment effects are 
displayed in supplementary table 2. Scenario analyses for patients at a starting age of 55 and 75 
years were also included. 
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The model was developed using Microsoft Excel® 2016 (Redmond, WA, USA, available from 
https://www.office.com/ [accessed August 31, 2018]). 
Figure 1. Schematic representation of the chronic heart failure Markov model. ICU, intensive 
care unit.  
Target population 
HF-REF patients, as described in PARADIGM-HF, were followed through the Markov model.19 
At the time of writing, sacubitril/valsartan is only registered for use within this group.18 The 
starting age was the mean age of the trial: 64 years, with scenarios for patients with a starting age 
of 55 and 75 years.19 If no data were available for the HF-REF group or a specific age category, 
data for the general CHF population were used. 
Comparators 
Primarily, sacubitril/valsartan was compared to enalapril, an ACEi, as in the PARADIGM-HF 
trial.19 German guidelines recommend the prescription of an ACEi to all HF-REF patients. If  an 
ACEi is not tolerated, an angiotensin receptor blocker (ARB) can be used, such as valsartan or 
candesartan.33 The cost-effectiveness of sacubitril/valsartan was assessed using the German EF 
approach, which was constructed using three mutually-exclusive treatment options: placebo (no 
treatment); enalapril, representing the group of ACEis; and candesartan, representing the group 
of ARBs.4,5,34–36 For the base case, we included the differences in effects and costs of the four 
treatment options for the full time horizon. As no head-to-head trials were available for 
candesartan vs. sacubitril/valsartan placebo vs. sacubitril/valsartan and enalapril vs. candesartan, 
adjusted, indirect comparisons were performed.37,38 In supplementary figure 1 and supplementary 
table 3 further details are provided on the relative risks of all direct and indirect comparisons. 
Regarding ICU admissions, only comparative data on enalapril vs. sacubitril/valsartan was 
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found; patients on placebo and candesartan were assumed to have the same risk of an ICU 
admission as placebo.28 
Costs 
The costs in the model were taken from the perspective of the Statutory Health Insurance (SHI).4 
The exact input parameters can be found in supplementary table 4. The price of 
sacubitril/valsartan was used from the appraisal dossier for Germany: €6.66 per day.41 Other 
drug costs were taken from the German institute of medical documentation and information 
(dimdi) or the site of the SHI.42 Hospitalization costs were based on the German diagnosis 
related group (G-DRG) system and the method previously used by Schmidt et al.43,44 One-day, 
general and ICU hospitalization costs were determined by their respective DRG codes, 
considering the length-of-stay of PARADIGM-HF as reported by Packer et al., multiplied by the 
average German lumpsum (Landesbasisfallwerte).28,43,45 Outpatient care costs were added 
monthly to all patients in the model and consisted of both general practitioner and cardiologist 
costs, visited on average 1.8 times annually, distributed equally.46,47 Sickness allowance 
(Krankengeld) was not included in the model, as the starting age in the model is higher than the 
effective age of labour market exit, and were therefore assumed to be negligible.4,48 All costs 
were converted into 2018 euros.49 
Health outcomes and utilities 
The health outcomes considered in the model were: hospitalizations averted in the first 42 
modelled months, 42-months survival, life-years gained and QALYs gained. The 42-month 
follow-up period for survival and hospitalizations was selected as this corresponds to the total 
follow-up of PARADIGM-HF.19 For the QALY calculations, EQ-5D utility values from 
PARADIGM-HF were used, since no German-specific utilities were found in the literature.50,51 
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The baseline utility value was 0.78, a disutility value of 0.21 was used for hospitalized patients 
and for sacubitril/valsartan treatment a utility benefit of 0.011 was incorporated.50,51  
Time horizon and discounting 
A 30-year time horizon was used to approach a lifetime horizon, with a starting age of 64. Both 
costs and effects were discounted at 3%, with 0% and 5% used in scenarios, in line with the 
German guidelines.4 
Model outcomes 
Incremental cost-effectiveness ratio, sensitivity analyses and scenario analyses 
ICERs were constructed for placebo, enalapril and candesartan compared to sacubitril/valsartan, 
with the main outcome considered being enalapril compared to sacubitril/valsartan, enabling us 
to compare our outcomes to other cost-utility analyses. The increase in costs was divided by the 
increase in quality adjusted life years (QALYs). The ICERs reported are rounded to the nearest 
hundreds of euros. To study the uncertainty in the model, a probabilistic sensitivity analysis 
(PSA) was performed using 10,000 replications, leading to a conventional cost-effectiveness 
(CE) plane and a cost-effectiveness acceptability curve (CEAC), incorporating placebo, 
enalapril, candesartan and sacubitril/valsartan. For the univariate sensitivity analysis, a Tornado 
diagram was created to display the effects of the uncertainty of specific values, using the 80%-
120% interval of the means, recording the corresponding effects on the ICER of 
sacubitril/valsartan compared to enalapril. 
To account for potential changes in drug costs, various price points were included in the scenario 
analyses: for sacubitril/valsartan the daily costs of €3 and €10 were included. For enalapril and 
candesartan a price point of €1 per day was included. To see the effects of the extrapolation of 
costs and effects of sacubitril/valsartan, a scenario was included where the benefits and added 
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costs of sacubitril/valsartan were only included for the follow-up of the PARADIGM-HF trial: 
42 months. Additionally, the discount rates were varied to 0% and 5%. The starting ages of the 
cohort were also varied, by including 55 year-old an 75 year-old cohorts. 
Efficiency frontier 
As mentioned, the IQWIG guidelines recommend an alternative method to perform health 
technology assessment.4,5 The EF is drawn on an inverted CE plane between the non-dominated 
alternative current treatment options, the new intervention is then compared with respect to this 
(linearly extrapolated) frontier.4 Although the use of QALYs is not ruled out, their use are not 
mandated in Germany, as opposed to many other countries.3,4 The EF method was developed 
with the use of direct, disease-specific and clinical outcomes in mind, without the need to use 
QALYs.5 To create a usable EF, at least two non-dominated alternatives should be available next 
to the novel treatment that is considered for reimbursement. We designed an EF with placebo, 
enalapril, candesartan and sacubitril/valsartan. The uncertainty of the EF was considered by 
constructing a price-acceptability curve and calculating the net monetary benefit (NMB).10,52 The 
price-acceptability curve was plotted by calculating the daily price where sacubitril/valsartan 
would be situated precisely on the EF, and thus be cost-effective, for all replications of the 
Monte Carlo analysis. The median NMB and interquartile range for the introduction price of 
sacubitril/valsartan (€6.66 /day) was calculated, as well as the median daily price where the 
NMB was equal to zero, this being the highest price where sacubitril/valsartan could be 
considered cost-efficient (i.e. it is situated on the EF). Model replications where no EF could be 





Base case results 
The base case results are displayed in table 1. Sacubitril/valsartan costs more than enalapril, but 
both life years and QALYs are gained. In the sacubitril/valsartan group, over 2,000 
hospitalizations are prevented in the 30-year time horizon compared to the enalapril group. The 
base case ICER is €19,300/QALY for sacubitril/valsartan versus enalapril; enalapril and 
candesartan are cost-saving compared to placebo, mainly due to the decrease in the number of 
hospitalizations. 
No EF can be created for the base case, regardless of the considered outcome: enalapril 
dominates all other comparator treatment options, resulting in the inability to assess the 
efficiency of sacubitril/valsartan. Inverted base-case cost-effectiveness planes are displayed in 
supplementary figure 2. 
CE plane and CEAC 
Figure 2 displays CE planes, showing the results of the probabilistic sensitivity analysis. 
Compared to placebo, most iterations show additional costs for sacubitril/valsartan and savings 
for enalapril and candesartan. Enalapril and candesartan have similar costs and effects. The 
CEAC is displayed in Figure 3. If the willingness to pay is equal to the base-case ICER 
(€19,300/QALY), sacubitril/valsartan is the most likely treatment to be considered cost-effective, 
with a probability of 41%. 
Figure 2. Cost-effectiveness planes of enalapril, candesartan and sacubitril/valsartan 
compared to placebo; and sacubitril/valsartan compared to enalapril 




Although no EF could be constructed for the base case, this was possible in the probabilistic 
analysis. Table 2 shows that this was possible for 77.5% of model replications, when survival, 
life-years gained or QALYs were considered as outcomes of the analysis and for 31.4% of 
replications if reduced hospitalizations were considered. The median NMB for 
sacubitril/valsartan at its introduction price in Germany is similar for all included outcomes: 
around -€14,000. The median calculated daily price of sacubitril/valsartan where the NMB is 
equal to zero, ranges from €1.52 to €1.67, depending on the outcome considered. The price-
acceptability curves (Figure 4), display the probability of sacubitril/valsartan being cost-effective 
at different price points (costs are per day) for the included outcomes. 
Figure 4. Price-acceptability curves of the cost-effectiveness of sacubitril/valsartan 
 
Univariate sensitivity analysis and scenario analyses 
The univariate sensitivity analysis, displayed as a tornado diagram, with the ICER of 
sacubitril/valsartan compared to enalapril as the considered outcome, is displayed in 
supplementary figure 4. The ICER is mainly impacted by the effect of sacubitril/valsartan on the 
mortality, the costs of this drug and the utilities of HF patients in the home setting.  
The results of the impact on the ICERs of the various included scenario analyses are shown in 
supplementary table 5. Sacubitril/valsartan, enalapril and candesartan drug costs have a major 
impact on the results. As long as the daily price of enalapril and candesartan are not increased, 





At €6.66 per day for sacubitril/valsartan, the ICER compared to the current treatment enalapril is 
€19.300/QALY. To reach a probability of 90% of being cost-effective, a willingness-to-pay 
threshold of €45,000/QALY would have to be considered (figure 3). Using the EF approach, the 
base case does not result in interpretable results; as enalapril, the cheapest alternative considered, 
is dominating placebo and candesartan, resulting in the inability to draw an EF using the 
available treatment options. The median daily price of sacubitril/valsartan where the NMB is 
equal to zero (i.e. it is situated on the EF), ranges from €1.52 to €1.67. 
The CE plane (figure 2) displays the incremental costs and effects of enalapril, candesartan and 
sacubitril/valsartan as compared to placebo. Enalapril and candesartan are overlapping on the 
plane, due to their very similar costs and effects. However, the uncertainty surrounding 
candesartan is greater, mainly due to the method its effects are modelled: there was no direct 
comparison with enalapril available. Compared to the other interventions, sacubitril/valsartan is 
more effective and more expensive. The univariate sensitivity analysis shows that the impact on 
mortality of sacubitril/valsartan is the main driver of the cost-effectiveness, followed by its costs, 
the quality-of-life measurements in the outpatient setting and the reduction in hospitalizations 
caused by sacubitril/valsartan.  
Using the EF approach, sacubitril/valsartan could not be considered cost-effective in more than 
5% of model replications, at a daily price of €6.66, independent of the outcome considered. The 
different outcomes considered do not influence our results to a large degree. The outcomes used 
to construct the EF based on gained life years (42-month survival, total life years gained and 
QALYs gained) provided comparable results: the cost-effectiveness planes are very similar, the 
price-acceptability curves are overlapping and an EF could be constructed in almost 80% of 
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model replications. Using the decrease in hospitalizations to construct the EF gives a similar 
shaped price-acceptability curve, although a EF could only be constructed in about 30% of 
replications, moving the vertical intercept down. The interquartile range of the NMB is also 
considerably wider compared to the other outcomes considered. This difference can be explained 
by the larger benefit of enalapril on hospitalizations than on mortality, compared to candesartan 
(see also supplementary table 3).34,35   
As compared to our previously-reported results for the Netherlands, the base-case ICER is 
approximately the same (both around €19,000/QALY). Compared to previously-published 
ICERs for European countries, which range from €17,600 to €23,401 with an average of 
€20,676, our ICER for Germany is within this range.20–25 For Germany, Gandjour and Ostwald 
calculated an ICER of €23,401, a small difference when regarding their very different model 
design: the included discounts on sacubitril/valsartan, their inclusion of indirect medical costs 
and their adjustments to the PARADIGM-HF mortality rates, based on Germany-specific data.25 
This analysis has a number of limitations, first of all, for the inclusion of candesartan and 
placebo, we focused on the model parameters with the largest impact on the results: mortality 
and hospitalizations, as data on the other inputs were not available in scientific literature. This 
also limited the number of clinical outcomes we could consider for the EF. The comparison 
between sacubitril/valsartan and placebo or candesartan is indirect, as no clinical trials have been 
performed with these comparators; the same holds true for candesartan vs. enalapril – of course, 
this has been considered for the PSA. The selection of comparators has a major impact on the 
construction of the EF: next to placebo, we included two comparable and mutually-exclusive 
drugs, representing two large classes of drugs (ACEis and ARBs).5 These will however not be 
used as monotherapy in most patients and be combined with several other drugs, such as 
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diuretics and beta blockers, and possibly other treatments, such as a pacemaker or cardiac 
resynchronization therapy; these treatments cannot really be considered true alternatives in the 
context of the EF and were therefore not included as comparators to sacubitril/valsartan.5,19,33,36,53 
In addition to the EF analysis, IQWIG guidelines detail the calculation of the budget impact, that 
can also be used in the decision-making process.4 Notably, we considered the budget impact 
outside of the scope of this research, however, Gandjour and Ostwald previously reported a 
maximum annual increase of the German healthcare budget of €88 million, which corresponds to 
less than 0.04% of total SHI expenditure.25 
The median daily price where sacubitril/valsartan is situated on the EF (NMB=0) ranges from 
€1.52 to €1.67. Using the price indicated by the EF, the introduction price of sacubitril/valsartan 
would warrant negotiations by German decision makers, to further approach this price point. If 
the ICER would instead be used to assess the cost-effectiveness of sacubitril/valsartan in the 
German context, it would most likely be deemed cost-effective at market entry, as reported for 
other European countries.20–24  
This comparison marks a major difference in conclusions decision makers would draw using 
either the ICER or EF approach. If we consider a fixed budget for CHF alone, the EF may 
provide more relevant information for decision makers: the health gains per euro will not 
decrease as long as the treatment is on or above the frontier. However, if we accept that patented 
drugs are more expensive, due to the coverage of development costs, the EF approach is not very 
useful in this case, since currently there is no method to determine an acceptable price point for 
innovative drugs replacing generic drugs. The latter issue was also raised by Sculpher and 
Claxton: a disease area with a concentration of generics, will have a low acceptable price point 
for innovative drugs.7 Using both approaches (ICER and EF) simultaneously, which are not 
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mutually exclusive, as this research shows, may have benefits in the decision making process. If 
a new product has an ICER that is regarded cost-effective, but the efficiency, as determined 
using the EF is low, the results could still be used to negotiate a discount. This might be 
especially relevant for innovations with a potentially large budget impact. Additionally, the EF’s 
ability to consider various outcomes may be helpful if alternative outcomes, such as patient-
reported outcomes, are generated by clinical trials.54 We think it may be useful to perform 
similar comparisons in various other fields, where patented drugs reflect important treatment 
modalities, such as oncology. 
Currently, sacubitril/valsartan is only registered for the use in HF-REF patients, although this 
model partly uses data for the general CHF population. German guidelines advice to only treat 
patients with the new drug if patients still are symptomatic under enalapril.53 New data could 
improve knowledge regarding the long-term effects of the new drug and the certainty of its cost-
effectiveness. Additionally, the results of the PARAGON-HF trial, which is expected to be 
completed in 2019, can indicate whether sacubitril/valsartan improves clinical outcomes for CHF 
patients with a preserved ejection fraction.55,56 A Post-hoc analysis from PARADIGM-HF 
indicates that sacubitril/valsartan might improve glycaemic control, which could improve the 
cost-effectiveness considering a diabetes is a common comorbidity in this patient population.57,58 
As this outcome was not routinely assessed, this aspect could not be considered in our analysis 
and further research would be useful from a clinical point of view, as well as from an economic 
perspective.59   
In conclusion, our model shows that sacubitril/valsartan can be considered cost-effective, at its 
introduction price in Germany, when using globally-used methods to perform the economic 
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evaluation.10 In contrast, using the EF approach, a discount of around 75% for 
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59% 65% 64% 70% 
Life years 54,527 63,037 61,825 72,450 










Dominated - Dominated €19,300 
ICER values rounded to the nearest hundreds of euros 
















Number of model replications 
where an EF could be 
constructed 
31.4% 77.5% 77.5% 77.5% 
Median NMB at introduction 
price of sacubitril/valsartan 
[IQR] 
 -€14,300  
[-€11,600  ̶  -
€16,200]  
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€2.37] 
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Supplementary table 1 - transition probabilities used in the Markov model 
Transition Probability (monthly) References 
Outpatient - death 
(cardiovascular) 


























Mortality during ICU 
hospitalization 


















Supplementary table 2 - Treatment Effects, including uncertainty used for probabilistic 
sensitivity analysis 
Treatment effects Risk ratio [95% CI] Distribution References 
Sacubitril/valsartan 
(relative to enalapril) 












Placebo (relative to 
enalapril) 










Candesartan (relative to 
placebo) 
Mortality: 0.87 [0.74-1.03] 
Hospitalization: 0.68 
[0.57-0.81] 







Supplementary table 3 – average direct and indirect relative risks 
Hospitalization risk 
Placebo Enalapril Candesartan Sacubitril/valsartan 
Placebo - 0.858 0.879 0.72* 
Enalapril 1.188 - 1.02* 0.841 
Candesartan 1.159 0.98* - 0.83* 
Sacubitril/valsartan 1.39* 1.191 1.21* - 
*indirect comparison
Mortality 
Placebo Enalapril Candesartan Sacubitril/valsartan 
Placebo - 0.648 0.689 0.51* 
Enalapril 1.568 - 1.07* 0.771 
Candesartan 1.479 0.94* - 0.75* 
Sacubitril/valsartan 1.96* 1.301 1.33* - 
*indirect comparison
5 
Supplementary table 4 - cost input parameters 
Description Monthly costs (2018 
euros) 
 Reference 
Enalapril treatment  €9.07^ 10 
Sacubitril/valsartan treatment  €199.8* 11 
Candesartan treatment  €8.46^ 10 
Other CHF drugs+ treatment  €12.36 1,10 
Costs of outpatient CHF care (general 
practitioner and cardiologist) 
 €7.87 12,13 
Hospitalization length of stay Additional costs: 
general ward | ICU 
(2018 euros) 
14,15 
0 days €794.01 
1 day €2420.18 | €3543.58 
2 days €3550.52 | €5013.72 
3 days €4200.63 | €6483.85 
4 days €4850.75 | €7953.99 
5 days €5500.87 | €9424.12 
6 days €5500.87 | €10894.26 
>6 days €5500.87 | €10894.26 
^scenario analysis for €3 per day is included; *scenario analyses for €3 and €10 per day are 
included; +hydrochlorothiazide, digoxin, spironolactone and metoprolol, using the usage 
data from PARADIGM-HF and German reference pricing 
CHF: Chronic Heart Failure; ICU: Intensive Care Unit; LOS: length of stay 
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Base case €19,300 Dominating Dominating 
0% discounting rate €17,000 Dominating Dominating 
5% discounting rate €20,900 Dominating Dominating 
€3 per day for 
sacubitril/valsartan 
€7,600 Dominating Dominating 
€10 per day for 
sacubitril/valsartan 
€30,000 Dominating Dominating 
€1 per day for enalapril 
and candesartan 
€17,400  €900  €1,200 
No extrapolation of 
effects beyond 42 
months 
€17,000 Dominating Dominating 
Starting age: 55 years €19,600 Dominating Dominating 
Starting age: 75 years €18,800 Dominating Dominating 
ICER values rounded to the nearest hundreds of euros 
ICER: Incremental Cost-Effectiveness Ratio; QALY: Quality-Adjusted Life Year 
7 
Supplementary figure 1 - flowchart of included trials 
SOLVD: Studies Of Left Ventricular Dysfunction8 
CHARM-alternative: Candesartan in Heart failure: Assessment ofReduction in Mortality and 
morbidity-Alternative9 
PARADIGM-HF: Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin 
Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on 








Supplementary figure 2 - base-case inverted cost-effectiveness planes for various outcomes 
A: Decrease in hospitalizations (compared to placebo, first 42 months); B: 42-month 
survival; C: Average total life years; D: Average total QALYs 
QALY: Quality-adjusted life year 
9 
Supplementary figure 3 - NMB  for a range of daily prices of sacubitril/valsartan the various 
outcomes, including the interquartile range (dotted line)  
A: Decrease in hospitalizations (compared to placebo, first 42 months); B: 42-month 
survival; C: Average total life years; D: Average total QALYs 
NMB: Net Monetary Benefit 
10 
Supplementary figure 4 - tornado diagram of the univariate sensitivity analysis of the ICER 
of sacubitril/valsartan compared to enalapril 
QALY: Quality-Adjusted Life Year 
ICU: Intensive Care Unit 
11 
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